Stellar Biotechnologies, Inc. (SBOT) EPS Estimated At $-0.14

December 8, 2017 - By Dolores Ford

 Stellar Biotechnologies, Inc. (SBOT) EPS Estimated At $ 0.14

Analysts expect Stellar Biotechnologies, Inc. (NASDAQ:SBOT) to report $-0.14 EPS on December, 13.They anticipate $0.01 EPS change or 7.69 % from last quarter’s $-0.13 EPS. After having $-0.12 EPS previously, Stellar Biotechnologies, Inc.’s analysts see 16.67 % EPS growth. The stock increased 1.78% or $0.0194 during the last trading session, reaching $1.1104. About 58,060 shares traded or 10.71% up from the average. Stellar Biotechnologies, Inc. (NASDAQ:SBOT) has declined 60.19% since December 8, 2016 and is downtrending. It has underperformed by 76.89% the S&P500.

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin protein primarily in Europe, the United States, and Asia. The company has market cap of $11.68 million. It provides KLH, an immune-stimulating molecule used as an active pharmaceutical ingredient in various immunotherapies; and as an injectable product to assess immune response. It currently has negative earnings. The firm offers its KLH protein under the Stellar KLH brand.

More notable recent Stellar Biotechnologies, Inc. (NASDAQ:SBOT) news were published by: which released: “Stellar Biotechnologies Inc.” on November 05, 2015, also with their article: “Stellar Biotechnologies Reports Fiscal Year 2017 Financial Results” published on December 01, 2017, published: “Stellar Biotechnologies Expands Operations Team” on June 07, 2017. More interesting news about Stellar Biotechnologies, Inc. (NASDAQ:SBOT) were released by: and their article: “Stellar Biotechnologies (SBOT) to Sell ‘Immunogen & Vaccine Technology’ to …” published on March 13, 2017 as well as‘s news article titled: “Stellar Biotechnologies: Vaccine Tech Buoyed By Partnerships” with publication date: June 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.